Saltar al contenido
Merck
  • Pharmacological Characterization of a Novel Beta 3 Adrenergic Agonist, Vibegron: Evaluation of Antimuscarinic Receptor Selectivity for Combination Therapy for Overactive Bladder.

Pharmacological Characterization of a Novel Beta 3 Adrenergic Agonist, Vibegron: Evaluation of Antimuscarinic Receptor Selectivity for Combination Therapy for Overactive Bladder.

The Journal of pharmacology and experimental therapeutics (2016-12-15)
J Di Salvo, H Nagabukuro, L A Wickham, C Abbadie, J A DeMartino, A Fitzmaurice, L Gichuru, A Kulick, M J Donnelly, N Jochnowitz, A L Hurley, A Pereira, A Sanfiz, G Veronin, K Villa, J Woods, B Zamlynny, E Zycband, G M Salituro, T Frenkl, A E Weber, S D Edmondson, M Struthers
RESUMEN

Although the physiologic role of muscarinic receptors in bladder function and the therapeutic efficacy of muscarinic antagonists for the treatment of overactive bladder are well established, the role of β

MATERIALES
Referencia del producto
Marca
Descripción del producto

Sigma-Aldrich
CL 316,243 hydrate, ≥98% (HPLC), powder
Sigma-Aldrich
Kits y reactivos de triglicéridos y glicerol libre, 1 kit sufficient for 1000 reactions
Sigma-Aldrich
Methoctramine hydrate, ≥97% (NMR), solid
Sigma-Aldrich
Darifenacin hydrobromide, ≥98% (HPLC)